Nestlé Health Science and Takeda participated in a series E round for Enterome, which received $52.6m in equity and debt financing through the deal.

France-based microbiome-focused therapy developer Enterome has closed $52.6m in financing, including series E equity funding featuring pharmaceutical firm Takeda and food producer Nestlé. The series E portion was led by microbiome investment vehicle Symbiosis and included Seventure Partners and its Health for Life Capital fund, Principia and Omnes Capital. Nestlé participated through its nutritional health…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.